- Re-Uptol (Escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults.
- Re-Uptol (Escitalopram) is also indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults.
Re-Uptol (Escitalopram) is an orally administered selective serotonin reuptake inhibitor (SSRI). The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). Re-Uptol (Escitalopram) is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Re-Uptol (Escitalopram) has no or very low affinity for serotonergic (5-HT1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine receptors. Re-Uptol (Escitalopram) also does not bind to, or has low affinity for, various ion channels including Na+, K+, Cl-, and Ca++ channels.
Re-Uptol is available in Alu-Alu Blister packing of 10 Tablets.